Dr. Minodora Brimpari
Abschluss: M.B.A, EU Business School
Munich, Deutschland
Werdegang
Berufserfahrung von Minodora Brimpari
• To establish a GMP-manufacturing programme for a stem-cell-based product to treat patients with Type 1 diabetes • Coordinate regulatory activities and interaction with competent authorities • Member of the EU-funded ISLET consortium that pioneers a new advanced cell therapy for Type 1 diabetes
1. Spearheaded and designed projects using pluripotent stem cell lines to develop new applications for cell therapy 2. Derived numerous human induced pluripotent stem cell lines (hIPSCs) to study mechanisms that induce variability in these lines 3. Non-CG DNA methylation is a biomarker for assessing endodermal differentiation capacity in pluripotent stem cells. Nature Communications
6 Monate, Sep. 2005 - Feb. 2006
Visitor Research Scientist
Imperial College London
Supervised an interdepartmental project on T-cell migration, and conducted analysis and summaries for result presentation and grant proposals
1 Jahr und 2 Monate, Juni 2002 - Juli 2003
Internship in Quality Control Microbiology Laboratory
Solvay Pharmaceuticals GmbH
Involved in the quality control of medicinal products
5 Monate, Juni 1999 - Okt. 1999
Internship in Microbiology Laboratory
Sismanogleio General Hospital, Greece
Collected and analysed patients samples
Ausbildung von Minodora Brimpari
9 Monate, Okt. 2015 - Juni 2016
Master in Business Administration
EU Business School
Dissertation Title: The Role of Pharmaceutical Companies to Engage with Social Media
5 Jahre, Okt. 2006 - Sep. 2011
Stem cell biology- Immunology
University of Cambridge
Investigated the immunogenicity of pluripotent stem cell lines for cell therapy
1 Jahr, Okt. 2004 - Sep. 2005
Immunology
Imperial College London
Immunology
3 Jahre und 10 Monate, Sep. 2000 - Juni 2004
Medical Microbiology
University of Surrey
Medical Microbiology
Sprachen
Englisch
Fließend
Griechisch
Muttersprache
Französisch
Grundlagen
Deutsch
Gut